Herst
Charles Vincent Taylor Herst, Oakland, CA US
Patent application number | Description | Published |
---|---|---|
20120231044 | VACCINE FORMULATION OF MANNOSE COATED PEPTIDE PARTICLES - A vaccine formulation as disclosed which is comprised of a pharmaceutically acceptable carrier in a plurality of particles with mannose on their surface. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence which corresponds to a sequence on a surface of a pathogen. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than a single particle from being presented to a single immune system cell. | 09-13-2012 |
20140105970 | ADJUVANT AND ANTIGEN PARTICLE FORMULATION - A composition as disclosed is comprised of a plurality of particles and a pharmaceutically acceptable carrier. The particles are comprised of (1) an adjuvant; (2) a biocompatible polymer which maybe a co-polymer such as PLGA, and (3) a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. The carrier includes an adjuvant such as a monophosphoryl lipid A (MPL) different from the adjuvant in the particles. The particles may be sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell. | 04-17-2014 |
C.v. Taylor Herst, Oakland, CA US
Patent application number | Description | Published |
---|---|---|
20090197281 | METHODS FOR DIAGNOSIS AND TREATMENT OF CHRONIC IMMUNE DISEASES - Methods are provided for diagnosing and/or characterizing chronic immune disease activity in a subject. In the subject methods, a sample is obtained from a subject suspected of having or known to have a chronic immune disease. The sample is then assayed for the presence of native Stat-1 protein and/or any lower molecular weight fragments of Stat-1 protein present. The assay results are used to diagnose the presence of chronic immune disease activity and/or characterize chronic immune disease activity in the subject, e.g., to confirm an initial chronic immune disease diagnosis, to determine the stage of the disease, to monitor disease progression, to predict disease attacks, and the like. In certain embodiments, the assay results are also used to predict the effectiveness of a particularly treatment protocol, e.g., to determine whether an interferon based treatment protocol will be effective. In addition, methods of Stat-1 based methods of treating chronic immune disease conditions are provided. Also provided by the subject invention are kits for practicing the methods. | 08-06-2009 |
Josh Herst, Seattle, WA US
Patent application number | Description | Published |
---|---|---|
20130046586 | SYSTEM AND METHOD FOR ASSESSING QUALITY OF TRANSIT NETWORKS AT SPECIFIED LOCATIONS - A system and method is disclosed for generating and providing assessments of transit network characteristics for specified locations. The system receives a specified location, generates an assessment of the received location, and provides a generated visual representation of the received location to a client system. Determining a location assessment may be based on transit network information related to the distance between a specified location and the nearest point of access/egress on transit network routes that are accessible from the specified location, the frequency at which the transit network routes stop at the point of access/egress on the transit network routes that are accessible from the indicated location, or the transportation mode used for at least one of the transit network routes that are accessible from the specified location. The initial location assessment may be updated periodically, in response to changes in system status, or on demand by user request. | 02-21-2013 |
20130046795 | SYSTEM AND METHOD FOR THE CALCULATION AND USE OF TRAVEL TIMES IN SEARCH AND OTHER APPLICATIONS - A system and method are provided for generating travel sheds which show the area reachable in a given amount of time by different modes of transport. A travel shed may consist of a series of polygons or other geometric shapes showing areas reachable from a given address or location within a specified travel time utilizing a specified mode of transport (e.g. driving, biking, walking, public transportation, etc.). Techniques are disclosed for enabling rapid calculations of travel times. In one embodiment, rapid generation of travel times and associated travel sheds may be enabled by performing pre-processing steps (e.g. downsampling, progressive road type removal, etc.) on road graph data. The pre-processing steps reduce the road graph while still preserving enough to generate accurate travel sheds. One example use of travel sheds is to enable searching for points of interest (e.g. homes, apartments, hotels, restaurants, schools, parks, etc.) according to specified travel times. | 02-21-2013 |
Joshua R. Herst, Seattle, WA US
Patent application number | Description | Published |
---|---|---|
20150026088 | CRIME ASSESSMENT TOOL AND METHOD - Embodiments of the disclosure are directed towards a crime assessment tool and method for comparing and visualizing crime statistics in a manner such that an accurate assessment of safety in one area may be compared to the safety in another area. The crime statistics may be normalized based on a population basis and/or on crime severity. The areas for comparison may be specified at various levels, such as cities, neighborhoods, specific addresses, or the like. Trending information may be visually provided to aid in assessing the safety of different areas. | 01-22-2015 |
Patries Herst, Wellington NZ
Patent application number | Description | Published |
---|---|---|
20120039917 | IMMUNOMODULATING ACTIVITIES - Composition of isoflavonoids and chromanols and use of them as immunomodulators and as inhibitors of T-cell or T-lymphocyte proliferation. Treatment of disorders involving abnormal proliferation or activity of T cells. Formula (I) where A is hydrogen or optionally substituted phenyl and R1 represents hydroxy, alkoxy, halo or an ester and R2-R8 represent hydogen, hydroxy, alkyl etc. | 02-16-2012 |